Gastrointestinal Imaging

What Is the Best Imaging for Primary Liver Cancer Screening in Adults?

·
What Is the Best Imaging for Primary Liver Cancer Screening in Adults?

A 64-year-old man with a history of cirrhosis secondary to chronic hepatitis C infection presents for his routine six-month follow-up. He is asymptomatic, and his liver function tests are stable. You know that his underlying condition places him at high risk for developing hepatocellular carcinoma (HCC), and the goal is to detect any potential malignancy at an early, treatable stage. The clinical question is clear: what is the most appropriate imaging study to order for routine screening in this high-risk patient? This article provides a detailed workflow for this specific scenario, based on the American College of Radiology (ACR) Appropriateness Criteria, which rates abdominal ultrasound as Usually appropriate for this indication.

Who Is a Candidate for Primary Liver Cancer Screening?

This guidance applies specifically to adults with established risk factors for primary liver cancer who are undergoing routine screening. The primary inclusion criterion is the presence of cirrhosis from any cause, including viral hepatitis (B or C), alcohol-related liver disease, or nonalcoholic steatohepatitis (NASH). Certain non-cirrhotic patients with chronic hepatitis B infection also meet the criteria for screening based on guidelines from hepatology societies. The goal of screening is to detect HCC in asymptomatic, high-risk individuals.

It is critical to distinguish this screening scenario from other clinical presentations:

  • Patients with a newly discovered liver mass: If a liver lesion is incidentally found on imaging performed for another reason (e.g., a CT for abdominal pain), the workup shifts from screening to diagnosis and characterization.
  • Patients with a confirmed HCC diagnosis: Once HCC is diagnosed, the imaging objective changes to staging the disease to determine the extent of cancer and guide treatment. This falls under the Adult. Primary liver cancer. Staging. scenario.
  • Patients with a known liver lesion under observation: A patient with a previously identified, indeterminate liver observation that is being monitored is managed under the Adult. Primary liver cancer. Liver observations under active surveillance. scenario.

Applying this screening workflow to patients who do not fit the high-risk profile is not appropriate and can lead to unnecessary testing and diagnostic cascades.

What Are You Screening For in a High-Risk Liver?

In this screening context, the primary objective is the early detection of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. Patients with cirrhosis undergo a continuous process of liver cell injury and regeneration, which creates a fertile ground for malignant transformation. Screening aims to identify HCC when tumors are small and have not invaded blood vessels, as these early-stage cancers are potentially curable with treatments like resection, transplantation, or ablation.

While HCC is the main target, screening ultrasound can identify other relevant findings within the cirrhotic liver:

  • Dysplastic Nodules: These are considered premalignant lesions. While ultrasound cannot definitively distinguish high-grade dysplastic nodules from small, well-differentiated HCC, their detection often triggers more intensive surveillance or a switch to higher-resolution cross-sectional imaging.
  • Regenerative Nodules: These benign nodules are ubiquitous in a cirrhotic liver and represent the liver’s response to injury. A key challenge for any imaging modality is to differentiate these from suspicious nodules that may represent early malignancy.
  • Other Malignancies: Although less common in this specific risk population, intrahepatic cholangiocarcinoma is another primary liver cancer that may be detected during screening.

The fundamental goal is to find any new or growing focal lesion that warrants further characterization.

Why Is Abdominal Ultrasound the Recommended Screening Study?

The ACR designates US abdomen as Usually appropriate for screening high-risk adults for primary liver cancer. This recommendation is based on a strong balance of diagnostic utility, safety, and practicality for a surveillance program that requires repeated imaging, typically every six months.

The rationale for preferring ultrasound as the initial screening tool is multifaceted:

  • Safety and Accessibility: Ultrasound is non-invasive, widely available, and comparatively inexpensive. Crucially, it uses no ionizing radiation (0 mSv), a vital consideration for a test that will be performed biannually for many years. It also avoids the need for intravenous contrast agents, eliminating risks related to allergic reactions or contrast-induced nephropathy.
  • Diagnostic Performance: For the specific task of detection, ultrasound has demonstrated acceptable sensitivity for identifying early-stage HCC. While its performance can be limited by patient body habitus, overlying bowel gas, or advanced, heterogeneous cirrhosis, it remains the established first-line modality in major societal guidelines.
  • Comparison to Alternatives: Other powerful imaging modalities are available but are rated lower for the initial screening step due to tradeoffs in risk, cost, and complexity.
  • CT abdomen with IV contrast multiphase is rated May be appropriate. While excellent for characterizing and staging a known or suspected lesion, its use for routine screening is discouraged due to significant radiation exposure (☢☢☢☢ 10-30 mSv) and the risks of repeated IV contrast administration. Its role is reserved for diagnostic workup after an abnormal ultrasound.
  • MRI abdomen without and with IV contrast is also rated May be appropriate. MRI offers superior soft tissue contrast and is the most sensitive and specific non-invasive test for characterizing liver lesions. However, its higher cost, longer acquisition time, and more limited availability make it impractical as a mass screening tool for the entire at-risk population. Like multiphase CT, its primary role is in the diagnostic phase.

A key ordering pearl is to recognize that the quality of a screening ultrasound is highly dependent on the skill of the sonographer and the interpreting radiologist. Examinations performed at centers with experience in hepatic imaging are preferred.

What Is the Next Step After the Screening Ultrasound?

The results of the screening ultrasound dictate the subsequent clinical pathway, which is well-defined by systems like the Liver Imaging Reporting and Data System (LI-RADS). The downstream workflow is a critical decision tree for the ordering clinician.

  • Negative Result: If the ultrasound is negative for any suspicious focal lesion, the patient should continue routine surveillance. The standard recommendation is to repeat the screening abdominal ultrasound in six months.
  • Sub-threshold Observation (<1 cm): If a new nodule smaller than 1 cm is detected, it is generally considered too small to characterize accurately. The standard recommendation is to initiate a period of closer surveillance, often with a follow-up ultrasound in three to six months to assess for stability or growth.
  • Positive Result (Observation ≥1 cm): The detection of a new or growing nodule of 1 cm or larger on a screening ultrasound is the primary trigger for a diagnostic workup. The patient should be referred for a multiphasic, cross-sectional imaging study. The next step is typically one of the following:
  • Multiphase CT abdomen with IV contrast
  • Multiphase MRI abdomen with IV contrast

The choice between CT and MRI for characterization depends on institutional preference, radiologist expertise, and patient-specific factors like renal function or contraindications to MRI. This next study aims to identify the characteristic enhancement patterns of HCC (arterial phase hyperenhancement and delayed phase “washout”) to make a non-invasive diagnosis, moving the patient from the screening workflow to a staging and treatment planning pathway.

Pitfalls to Avoid (and When to Get Help)

Navigating liver cancer screening requires vigilance to avoid common pitfalls that can compromise patient outcomes.

  • Inadequate Ultrasound Technique: A suboptimal ultrasound due to patient factors (e.g., obesity, bowel gas) or technical limitations can lead to a false-negative result. If the report indicates a “technically limited study,” consider proceeding to a cross-sectional study (CT or MRI) for that screening interval.
  • Ignoring Growth: A small nodule that has grown compared to prior studies, even if it remains under 1 cm, is a worrisome feature. This finding should prompt a lower threshold for proceeding to diagnostic CT or MRI.
  • Over-reliance on AFP: While serum alpha-fetoprotein (AFP) is often ordered alongside ultrasound, it has poor sensitivity and specificity. A normal AFP level does not exclude HCC, and an elevated level can be seen in other conditions. Imaging remains the cornerstone of screening.
  • Delaying Diagnostic Workup: Once a suspicious lesion (≥1 cm) is found on screening ultrasound, the follow-up multiphase CT or MRI should be performed promptly to confirm the diagnosis and allow for timely treatment.

If a definitive HCC diagnosis is made, or if there is evidence of vascular invasion or extrahepatic disease, the patient’s care should be escalated to a multidisciplinary tumor board including hepatologists, surgeons, interventional radiologists, and oncologists.

Related ACR Topics and Tools

This article focuses on a single clinical scenario. For a comprehensive overview of imaging across the entire disease process, from staging to post-treatment follow-up, please consult the parent topic guide. Additional tools are available to help select the right test and understand the technical details.

Frequently Asked Questions

How often should screening ultrasound be performed for primary liver cancer?

For most high-risk patients, including those with cirrhosis, major societal guidelines recommend screening with an abdominal ultrasound every six months. This interval is chosen to balance the likelihood of detecting tumors at an early stage against the burden and cost of more frequent testing.

Is it ever appropriate to use CT or MRI as the primary screening tool instead of ultrasound?

While the ACR rates multiphase CT and MRI as ‘May be appropriate,’ they are generally not recommended for first-line, routine screening for the entire at-risk population due to factors like radiation dose (for CT), higher cost, and lower availability compared to ultrasound. However, in a patient for whom ultrasound is known to be severely technically limited (e.g., due to severe obesity or ascites), a clinician might consider alternating with or using CT or MRI as the primary screening tool after a multidisciplinary discussion.

What is the role of the blood test alpha-fetoprotein (AFP) in screening?

Alpha-fetoprotein (AFP) is a tumor marker that is often measured in the blood every six months along with the screening ultrasound. However, its role is controversial. AFP can be normal in many patients with early-stage HCC and can be elevated for other reasons, such as a flare of hepatitis. Therefore, it is considered an adjunct to imaging, not a replacement. A normal AFP does not rule out cancer, and an abnormal ultrasound should be followed up with diagnostic imaging regardless of the AFP level.

If a screening ultrasound finds a cyst or hemangioma, what is the next step?

If the ultrasound report confidently identifies a finding as a simple cyst or a typical hemangioma, these are benign lesions and generally require no further follow-up. The patient would simply continue with their routine six-month screening schedule. The primary goal of screening is to find new or indeterminate solid nodules.

Does this screening guidance apply to patients who have already had a liver transplant?

No, this guidance is for screening for primary liver cancer in a patient’s native, at-risk liver. Patients who have undergone a liver transplant for HCC or other reasons follow a different post-transplant surveillance protocol to monitor for tumor recurrence or other complications in the transplanted liver. That represents a distinct clinical scenario.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026